within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX21_Eplontersen;

model Eplontersen
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.666666666666667e-08,
    adminDuration = 600,
    adminMass = 45 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.007,
    k12 = 8.055555555555555e-08,
    k21 = 8.055555555555555e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Eplontersen</td></tr><tr><td>ATC code:</td><td>N07XX21</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>45</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.24</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Eplontersen is an antisense oligonucleotide inhibitor of transthyretin (TTR) synthesis, aiming to reduce serum TTR protein levels. It is developed for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in adults. In 2023, Eplontersen (brand name Wainua) was granted FDA approval for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for subcutaneous administration in adult patients; no peer-reviewed publication with detailed PK model found as of June 2024.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N07XX21 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Eplontersen;
